Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Amyloid still means something in Alzheimer’s research, but it means less than the medical field once believed. For decades, amyloid-beta plaques were treated as the primary target in Alzheimer’s disease—the villain that needed to be eliminated to stop cognitive decline. That assumption has proven more complicated. Two FDA-approved therapies, Leqembi® (lecanemab) and Kisunla™ (donanemab), do target amyloid and have shown the ability to clear these plaques from the brain. Yet a major Cochrane systematic review published in April 2026 examining 17 randomized controlled trials with over 20,342 participants concluded that these amyloid-targeting monoclonal antibodies result in “little to no difference” in cognitive function, dementia severity, or functional ability at 18 months.
The effect size itself was described as “trivial.” What this shift means is that amyloid remains part of the Alzheimer’s story—but no longer as the whole story. The plaques matter enough that clearing them shows measurable cognitive slowing over 3-4 years with continued treatment, yet the benefit is modest enough that researchers and clinicians now recognize amyloid as one piece of a much larger puzzle. The brain changes involved in Alzheimer’s involve tau protein, inflammation, vascular dysfunction, and immune system changes alongside amyloid. As a result, amyloid-targeting drugs now represent only 20% of the entire Alzheimer’s drug development pipeline, down from one-third a decade ago. This recalibration isn’t a failure of amyloid science—it’s a maturation of it. Understanding why amyloid treatments show real but limited benefit, what risks they carry, and where the field is turning next matters for anyone making treatment decisions or supporting someone in early Alzheimer’s disease.
Table of Contents
- How Did Amyloid Become the Focus of Alzheimer’s Research?
- What the Latest Clinical Evidence Actually Shows About Amyloid Treatments
- The Safety Trade-Off—Why ARIA Matters More Than Some Realize
- Beyond Amyloid—Why the Research Pipeline is Shifting
- What Early Alzheimer’s Patients Should Understand About These Drugs
- Long-Term Data and Realistic Expectations
- The Future of Alzheimer’s Treatment—Beyond Single-Target Approaches
- Conclusion
How Did Amyloid Become the Focus of Alzheimer’s Research?
Amyloid-beta became central to Alzheimer’s research through decades of neuropathology work. When researchers examined the brains of Alzheimer’s patients at autopsy, they consistently found extracellular amyloid plaques and intracellular tau tangles. In the 1990s, the amyloid cascade hypothesis emerged: amyloid accumulation was the initiating event that triggered a cascade of pathological changes, including tau tangles, neuroinflammation, and neuronal death. This hypothesis made amyloid seem like the logical therapeutic target—if you could stop amyloid before it triggered everything else, you might prevent Alzheimer’s entirely.
It was elegant, supported by genetics (mutations in genes affecting amyloid processing increase Alzheimer’s risk), and it led drug developers and funding agencies to pour resources into anti-amyloid strategies. Yet the amyloid-dominant model left key questions unanswered. Why do many people accumulate amyloid plaques in their brains but never develop cognitive symptoms? Why did decades of amyloid-lowering treatments fail to slow cognitive decline before Leqembi and Kisunla? And why, when lecanemab and donanemab do clear amyloid, is the cognitive benefit so modest? These questions have prompted a major reconsideration. Amyloid may be necessary for some Alzheimer’s pathology, but it appears insufficient as a sole target.
What the Latest Clinical Evidence Actually Shows About Amyloid Treatments
The Cochrane review of April 2026 provides the most comprehensive recent assessment of what anti-amyloid monoclonal antibodies actually achieve. In examining 17 trials involving over 20,342 participants, reviewers found that lecanemab and donanemab produce cognitive improvements on standardized tests that are statistically significant but clinically negligible at 18 months. For perspective, the cognitive decline in early Alzheimer’s is measurable and progresses—slowing it is meaningful—but the difference between amyloid-treated and control groups at 18 months was classified as “trivial.” The lecanemab trial (CLARITY-AD) provides the concrete numbers. Patients on lecanemab showed an amyloid PET reduction of −72.99 SUVr, a dramatic clearing of plaques from brain imaging. On the Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-Cog 14), the treatment effect yielded a standardized mean difference of −1.06.
The donanemab trial (TRAILBLAZER-ALZ 2) showed similar efficacy patterns, with both drugs meeting their primary and secondary endpoints. Both are modest benefits—the difference between treated and untreated groups accumulates over years, and long-term data suggest that cognitive benefit continues to grow with continued treatment over 3-4 years. But at the 18-month mark that most trials measure, the cognitive difference is small. A patient on lecanemab might show slightly slower decline in memory or thinking speed, but the change is often not immediately apparent to family members in real life. This modest benefit must be weighed against other considerations, including the risks of the drugs themselves.
The Safety Trade-Off—Why ARIA Matters More Than Some Realize
The most significant drawback of amyloid-targeting monoclonal antibodies is amyloid-related imaging abnormalities (ARIA)—brain changes visible on MRI that reflect inflammation or microhemorrhages triggered by rapid amyloid clearance. The Cochrane review found that patients on lecanemab or donanemab had a 4.35 times higher relative risk of ARIA compared to patients in control groups. These aren’t rare events. In clinical trials, 21-26% of patients on these drugs experienced ARIA-E (amyloid-related imaging abnormalities—edema, or brain swelling) and 17% experienced ARIA-H (hemorrhages or microhemorrhages). Most ARIA events are asymptomatic—patients develop the imaging finding without experiencing obvious symptoms—but some cause cognitive symptoms, headaches, or other neurological signs. Severe ARIA can require hospitalization and drug discontinuation.
The drugs require baseline MRI before treatment and periodic MRI monitoring during therapy to catch ARIA early. This adds cost, complexity, and anxiety for patients and families. One patient might tolerate the drug well and experience mild amyloid clearance. Another patient at the same dose develops significant ARIA and must stop. This unpredictability is a real limitation. The drugs are approved for early Alzheimer’s disease specifically because the amyloid-related risks are considered acceptable when caught early, but this isn’t a risk-free choice.
Beyond Amyloid—Why the Research Pipeline is Shifting
The modest benefit from amyloid-targeting drugs hasn’t killed interest in them, but it has redirected attention. Drug developers and researchers are now investing heavily in approaches that go beyond amyloid alone. Tau-targeting therapies are in development—tau protein tangles inside neurons appear to correlate more directly with cognitive symptoms than amyloid plaques do, and early research suggests tau-targeting might offer a different pathway. Anti-inflammatory approaches are being tested, based on evidence that neuroinflammation is a major driver of neurodegeneration in Alzheimer’s. Approaches targeting immune system function are emerging, as evidence accumulates that the brain’s immune cells (microglia) play a central role in both amyloid and tau pathology.
Recent research has identified two brain receptors involved in clearing amyloid-beta, and an enzyme called IDOL is emerging as a potential new therapeutic target. These discoveries suggest that instead of forcing amyloid clearance with monoclonal antibodies, future therapies might enhance the brain’s own natural ability to clear amyloid and other toxic proteins. Within 10 years, amyloid-targeting monoclonal antibodies may be just one tool in a much larger therapeutic toolkit. Current amyloid drugs represent only 20% of the Alzheimer’s drug pipeline, compared to one-third a decade ago. That shift reflects a realistic assessment: amyloid matters, but it doesn’t matter alone.
What Early Alzheimer’s Patients Should Understand About These Drugs
For someone recently diagnosed with early Alzheimer’s disease or mild cognitive impairment due to Alzheimer’s pathology, the decision to start lecanemab or donanemab involves understanding the real benefit alongside the real risks. These drugs are appropriate when: amyloid pathology is confirmed (via amyloid PET imaging or CSF biomarkers), cognitive symptoms are mild, a patient is willing to commit to regular MRI monitoring, and ARIA can be managed medically if it occurs. The cognitive benefit over 18 months is real but modest—more apparent over 3-4 years of continued treatment. However, these drugs are not appropriate for everyone with an Alzheimer’s diagnosis.
Patients with moderate to severe dementia don’t benefit—the drugs are approved only for early stages. Patients with significant cerebrovascular disease, prior stroke, or certain brain imaging abnormalities may face higher ARIA risk. Some patients prefer not to take the risk of ARIA monitoring and hospitalization for a modest cognitive benefit. Others view any slowing of decline as worth the trade-off. This is a genuinely individual decision that should be made with a neurologist or Alzheimer’s specialist, not based on marketing or pressure to “do something.” The drugs are an option, not a requirement, and they work best as part of a comprehensive approach that includes cognitive stimulation, physical activity, cardiovascular health management, and social engagement.
Long-Term Data and Realistic Expectations
Long-term safety and efficacy data from extended follow-up studies show that lecanemab continues to clear amyloid and produce cognitive benefits over years of treatment. One open-label extension study of lecanemab showed that patients who continued treatment maintained cognitive benefits, and the drug was generally well-tolerated over the long term when ARIA was managed properly. This suggests that the modest short-term benefit may accumulate over years, making the absolute difference in cognitive decline more substantial for patients who remain on treatment and tolerate it well. However, “long-term” data still spans only several years.
No drug has proven to halt or reverse Alzheimer’s disease entirely. The realistic expectation is cognitive slowing—delaying the progression from mild cognitive impairment to mild dementia by months to a few years—not stopping Alzheimer’s altogether. For some patients and families, delaying cognitive decline by 12-24 months provides meaningful extra time with preserved memory and function. For others, the emotional burden of monitoring for ARIA and the modest benefit don’t feel worth it. Both perspectives are reasonable.
The Future of Alzheimer’s Treatment—Beyond Single-Target Approaches
The future of Alzheimer’s treatment likely involves combination approaches rather than single drugs targeting single pathways. If amyloid targeting is modestly effective, tau targeting shows promise, and anti-inflammatory approaches work, combining them might produce additive benefit. Clinical trials testing combination strategies are already underway. Additionally, patient stratification is becoming more sophisticated—identifying which patients are most likely to benefit from which drug based on their specific biomarker profile, genetic risk factors, and brain imaging.
Emerging research on natural amyloid-clearing mechanisms offers another direction. If IDOL and other newly identified targets can be harnessed therapeutically, future treatments might work with the brain’s own systems rather than forcing amyloid clearance artificially. This could reduce ARIA risk while improving efficacy. For now, amyloid-targeting monoclonal antibodies represent the only disease-modifying therapies with demonstrated clinical benefit, but they won’t be the final word on Alzheimer’s treatment. The field is moving toward a more nuanced, multifaceted approach to a disease that is, itself, multifaceted.
Conclusion
Amyloid still means something in Alzheimer’s research—it remains part of the disease mechanism and targeting it does slow cognitive decline. But amyloid no longer means everything. The Cochrane review, the modest benefit observed in clinical trials, the emergence of safer alternatives, and the growing recognition of other pathological drivers have all repositioned amyloid from the centerpiece of Alzheimer’s research to one important piece of a larger puzzle. The two FDA-approved amyloid-targeting drugs, Leqembi and Kisunla, offer a real but modest cognitive benefit accompanied by real safety considerations, particularly the risk of amyloid-related imaging abnormalities.
For patients, families, and clinicians, this recalibration means making informed decisions rather than pursuing amyloid targeting as the default. It means recognizing that other approaches—tau-targeting, anti-inflammatory, immune-modulating—are becoming equally or more important in the treatment pipeline. It means understanding that comprehensive Alzheimer’s care involves not just medications but also cognitive engagement, physical activity, cardiovascular health, and social connection. The science of Alzheimer’s is evolving, becoming more precise and less driven by single hypotheses. Amyloid still matters—just not in the way researchers once believed it would.
You Might Also Like
- Why Alzheimer’s May Be More Complicated Than Amyloid Plaques
- What a Positive Alzheimer’s Blood Test Might Actually Mean
- What Hidden Alzheimer’s Triggers Could Mean for Prevention
Related reading
- why Gene Therapy for Alzheimer’s Is Still Early but Important
- can Genetic Medicine Help Prevent Brain Cell Damage
- could Alzheimer’s Treatments One Day Be Personalized by Gene Risk
- why APOE Research Still Matters in Alzheimer’s Disease
- could Editing Cholesterol Genes Affect Dementia Risk
For more on this topic, see Alzheimer’s Association.
